Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Feasibility Study of Whole Egg Consumption in Adults With Intermediate Age-related Macular Degeneration
Authors not listed
Kathryn Starr · 2025
Abstract
Age-related macular degeneration (AMD) is the primary cause of vision loss in people over the age of 55. Currently, no cure is available for individuals suffering from AMD. The purpose of this pilot study is to evaluate the feasibility of implementing a 5-month egg intervention in adults with intermediate AMD. The objective of this research study is to evaluate the feasibility of a whole egg (2 or 4 per day) intervention in older adults with intermediate AMD. The secondary objective of this research is to determine descriptive statistics, change over time and estimate effect sizes for retinal sensitivity, and vision, cognition and physical function. By completing these research objectives, the researchers hope to gain preliminary evidence in support of a larger trial that will assess the impact of egg consumption on eye health in adults with AMD.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-02 MST
Cite this
APA
Anonymous. (2025). Feasibility Study of Whole Egg Consumption in Adults With Intermediate Age-related Macular Degeneration. <em>Kathryn Starr</em>. https://clinicaltrials.gov/study/NCT07021027
Vancouver
Anonymous. Feasibility Study of Whole Egg Consumption in Adults With Intermediate Age-related Macular Degeneration. Kathryn Starr. 2025.
BibTeX
@misc{anon2025Feasib,
title = {Feasibility Study of Whole Egg Consumption in Adults With Intermediate Age-related Macular Degeneration},
author = {Anonymous},
journal = {Kathryn Starr},
year = {2025},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Tyrogenex 2012
Open access · US-GOV
A Phase 1 Open-label, Dose Escalation Clinical Trial to Evaluate the Safety and Preliminary Biologic Activity/Efficacy of the VEGFR/PDGFR Inhibitor X-82 Administered Per Os in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Center for Eye Research Australia 2021
Open access · US-GOV
Subthreshold Laser Treatment in Intermediate Age-related Macular Degeneration With Nascent Geographic Atrophy Study
Chengdu Kanghong Biotech Co., Ltd. 2011
Open access · US-GOV
An Open, Non-randomize, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration
Current developments in nutrition 2026
Open access · OA
Clinical Protocol for the Dietary Approaches to Longevity and Health (DiAL Health) Pilot Trial.
EyebioKorea, Inc. 2024
Open access · US-GOV
A Randomization, Double-blind, Parallel, Multicenter-Phase 2a Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration
Allergan 2007
Open access · US-GOV